This article is more than 5 years old. Information may no longer be current.
Interleukin-1 inhibitor meets efficacy criteria in study of dry eye disease
An interleukin-1 receptor antagonist met efficacy criteria in a phase 1b/2a study involving patients with dry eye disease, Eleven Biotherapeutics announced in a press release.
Compared with baseline, topical ocular administration of EBI-005 resulted in statistically significant improvements in signs and symptoms of dry eye disease and showed a differential effect between subjects who received EBI-005 and subjects who received placebo.
The double-masked, multicenter, randomized, placebo-controlled study involved two doses of EBI-005 in a 6-week period in 74 subjects with dry eye disease. The treatment was generally safe and well-tolerated.
“These clinical data of EBI-005 in patients with dry eye disease confirm other recent clinical results and further validate that [interleukin-1] inhibition targets a fundamental inflammatory process, showing that EBI-005 has the potential for beneficial results for patients with dry eye disease and other inflammatory diseases on the surface of the eye,” Reza Dana, MD, a founder and clinical adviser of Eleven Biotherapeutics, said in the release.
Plans are under way to advance EBI-005 into late-stage clinical studies for dry eye and other inflammatory diseases of the ocular surface, such as severe allergic conjunctivitis.